Monarch Partners Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Monarch Partners Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$4.16M	Sell	62,327 -33,186	-35%	-$2.16M	1.23%	18
2022 Q3	$5.13M	Buy	95,513 +20,864	+28%	+$1.23M	1.54%	5
2022 Q2	$4.16M	Buy	+74,649	New	+$4.24M	1.16%	12
2016 Q4	–	Sell	-54,951	Closed	-$3.5M	–	190
2016 Q3	$3.5M	Buy	+54,951	New	+$4.03M	0.33%	97

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Monarch Partners Asset Management's LGND Position: Q4 2022 in Review

Monarch Partners Asset Management reduced its Ligand Pharmaceuticals (LGND) stake by 35% in Q4 2022, selling an estimated $2.16M and leaving 62,327 shares worth $4.16M. The position accounts for 1.23% of the portfolio, ranked #18.

Monarch Partners Asset Management first reported a position in LGND in Q3 2016 and has held it in 4 quarters since. The position peaked at $5.13M in Q3 2022. 198 funds tracked by Wall St. Rank hold LGND as of Q4 2022.

Monarch Partners Asset Management held 62,327 shares of Ligand Pharmaceuticals worth $4.16M as of Q4 2022.
Monarch Partners Asset Management sold 33,186 Ligand Pharmaceuticals shares in Q4 2022, an estimated $2.16M.
Ligand Pharmaceuticals made up 1.23% of Monarch Partners Asset Management's portfolio in Q4 2022, its #18 holding.
Monarch Partners Asset Management first reported a position in Ligand Pharmaceuticals in Q3 2016 and has held it in 4 quarters since.
Monarch Partners Asset Management's Ligand Pharmaceuticals position peaked at $5.13M in Q3 2022.
198 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2022.

Based on Monarch Partners Asset Management's 13F filing for Q4 2022, filed 2 Feb 2023.